Atenguena Etienne Okobalemba, Ndjeutcham Astryde Larissa Tchutchou, Kamdem Vanelle Lotie Messah, Mbopda Estelle Alida Ngne, Mayemi Manuella, Menzy Carole Marlise, Zingue Stéphane
Oncology Division, Yaoundé General Hospital, Yaoundé, Cameroon.
Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, P.O. Box 1364 Yaoundé, Cameroon.
Pan Afr Med J. 2025 Mar 18;50:79. doi: 10.11604/pamj.2025.50.79.43589. eCollection 2025.
digestive cancers (DC) are a group of cancers affecting the gastrointestinal tract and are capable of triggering an immune response. The cells produced during this response are tumor effectors whose role is to rid the body of tumor cells. The functional role of these cells, particularly the tumor-infiltrating lymphocytes (TILs), in the prognosis of patients remains poorly understood in Cameroon. This study aimed to evaluate the impact of lymphocyte infiltration on the survival of patients with certain digestive cancers.
we conducted a retrospective cross-sectional study at the Oncology Department and the Anatomo-Cytopathology Laboratory of the Yaoundé General Hospital (YGH). Patients histologically diagnosed with colorectal and gastric cancers with available data from YGH between 2019 and 2023, who consented to participate and had a biopsy sample available at the YGH laboratory, were included in the study. Initially, we described patients' sociodemographic, clinical, and pathological characteristics. Then, we estimated the grade of lymphocyte infiltration in colorectal and gastric cancers using Hematoxylin-Eosin (HE) staining and analyzed the correlation between lymphocyte infiltration and patient survival through Cox regression. Data were analyzed with a significance level set at 5% for all comparisons.
the study enrolled 90 patients with colorectal cancer and 50 with gastric cancer. Overall survival was 64.8% at 49 months in the study population, with the median not reached for colorectal cancer, and 64% at 39 months for gastric cancer, also with a median not reached. The average age at diagnosis for colorectal and gastric cancers was 54 ± 14.53 years and 53.24 ± 11.41 years, respectively. Men predominated in both pathologies, with a sex ratio of approximately 1.11. Colonic location was predominant (53%; 46/90) for colorectal cancer, with stage III disease being most common, while the antropyloric location (46%; 23/50) was predominant for gastric cancer, with stage IV being most frequent according to the AJCC. Moreover, 86% of patients had TILs in their histological samples, with a predominance of high TILs in both colorectal (38%; 34/90) and gastric (42%; 21/50) cancers. The performance of chemotherapy was inversely proportional to TILs in colorectal cancer, while no significant difference was found between TILs and chemotherapy in gastric cancer. However, no association was found between TILs and patient survival in either colorectal or gastric cancers. Patients who had metastases had a risk of death of 14.07 (aHR: 14.07, 95% CI 1.66-119.24; p = 0.015) compared with those who did not. Similarly, patients who had not taken chemotherapy had a 21.32 greater risk of death (aHR: 21.32, 95% CI 5.35-84.96; p<0.001) than those who had.
there was no statistically significant difference in survival between patients suffering from colorectal and gastric cancers, and the grade of lymphocyte infiltration. Survival was significantly impacted by the presence of metastasis and the absence of treatment.
消化系统癌症(DC)是一组影响胃肠道的癌症,能够引发免疫反应。这种反应过程中产生的细胞是肿瘤效应细胞,其作用是清除体内的肿瘤细胞。在喀麦隆,这些细胞,特别是肿瘤浸润淋巴细胞(TILs)在患者预后中的功能作用仍知之甚少。本研究旨在评估淋巴细胞浸润对某些消化系统癌症患者生存的影响。
我们在雅温得综合医院(YGH)的肿瘤科和解剖细胞病理学实验室进行了一项回顾性横断面研究。纳入2019年至2023年期间在YGH进行组织学诊断为结直肠癌和胃癌且有可用数据、同意参与并在YGH实验室有活检样本的患者。首先,我们描述了患者的社会人口统计学、临床和病理特征。然后,我们使用苏木精-伊红(HE)染色评估结直肠癌和胃癌中淋巴细胞浸润的程度,并通过Cox回归分析淋巴细胞浸润与患者生存之间的相关性。所有比较的数据分析设定显著性水平为5%。
该研究纳入了90例结直肠癌患者和50例胃癌患者。研究人群在49个月时的总生存率为64.8%,结直肠癌患者的中位生存期未达到,胃癌患者在39个月时的总生存率为64%,中位生存期也未达到。结直肠癌和胃癌的诊断平均年龄分别为54±14.53岁和53.24±11.41岁。两种病理类型中男性居多,性别比约为1.11。结直肠癌以结肠部位为主(53%;46/90),III期疾病最常见,而胃癌以胃窦部为主(46%;23/50),根据美国癌症联合委员会(AJCC)分期,IV期最常见。此外,86%的患者组织学样本中有TILs,结直肠癌(38%;34/90)和胃癌(42%;21/50)中高TILs均占优势。在结直肠癌中,化疗效果与TILs呈反比,而在胃癌中,TILs与化疗之间未发现显著差异。然而,在结直肠癌或胃癌中,均未发现TILs与患者生存之间存在关联。有转移的患者与无转移的患者相比,死亡风险为14.07(调整后风险比:14.07,95%置信区间1.66 - 119.24;p = 0.015)。同样,未接受化疗的患者与接受化疗的患者相比,死亡风险高21.32倍(调整后风险比:21.32,95%置信区间5.35 - 84.96;p<0.001)。
结直肠癌和胃癌患者的生存率以及淋巴细胞浸润程度之间没有统计学上的显著差异。转移的存在和未接受治疗对生存率有显著影响。